BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 5067566)

  • 1. Familial incidence of long-acting thyroid stimulator (LATS) in Graves' disease.
    Bonnyns M; Vanhaelst L
    Horm Metab Res; 1972 Mar; 4(2):132. PubMed ID: 5067566
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma LATS and thyroid antibody level, and the clinical manifestations of Graves' disease.
    Földes J; Takó J; Bános C; Gesztesi E; Varga I
    Acta Med Acad Sci Hung; 1969; 26(3):233-43. PubMed ID: 5395883
    [No Abstract]   [Full Text] [Related]  

  • 3. [LATS(long-acting thyroid stimulator): recent development].
    Shishiba Y
    Naika; 1971; 28(1):48-52. PubMed ID: 4935654
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hyperthyroidism and the "long acting thyroid stimulator" (LATS)].
    Studer H
    Schweiz Med Wochenschr; 1967 May; 97(19):622-3. PubMed ID: 5632362
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
    Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-acting thyroid stimulator (LATS), thyrotropin (TSH) and the pathogenesis of hyperthyroidism].
    Lamberg BA; Gordin A
    Nord Med; 1968 Dec; 80(49):1651-7. PubMed ID: 5757398
    [No Abstract]   [Full Text] [Related]  

  • 7. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
    Silverstein GE; Burke G
    Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002
    [No Abstract]   [Full Text] [Related]  

  • 8. [LATS and Graves' disease].
    Gordon A
    Harefuah; 1971 May; 80(10):569-70. PubMed ID: 5171988
    [No Abstract]   [Full Text] [Related]  

  • 9. [The long acting thyroid stimulator (LATS) in some thyroid diseases. Preliminary results].
    Busnardo B; Accordi F; Debiasi S
    Acta Isot (Padova); 1968 Oct; 8(2):165-79. PubMed ID: 5761578
    [No Abstract]   [Full Text] [Related]  

  • 10. [The determination of long-acting thyroid stimulator (LATS) in thyroid diseases].
    Depisch D; Höfer R; Schatz H
    Wien Z Inn Med; 1968; 49(4):121-30. PubMed ID: 5757238
    [No Abstract]   [Full Text] [Related]  

  • 11. [New ideas on the regulation of thyroid function by LATS (long-acting thyroid stimulator) and their repercussion on human pathology].
    Strumia E
    Minerva Med; 1967 Nov; 58(90):3879-85. PubMed ID: 5630606
    [No Abstract]   [Full Text] [Related]  

  • 12. LATS and Graves' disease.
    Soloman DH; Chopra IJ
    Calif Med; 1970 Aug; 113(2):50-5. PubMed ID: 5538194
    [No Abstract]   [Full Text] [Related]  

  • 13. Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease.
    McKenzie JM; McCullagh EP
    J Clin Endocrinol Metab; 1968 Aug; 28(8):1177-82. PubMed ID: 4175472
    [No Abstract]   [Full Text] [Related]  

  • 14. Does LATS cause hyperthyroidism in Graves' disease? (A review biased toward the affirmative).
    McKenzie JM
    Metabolism; 1972 Sep; 21(9):883-94. PubMed ID: 4115791
    [No Abstract]   [Full Text] [Related]  

  • 15. Large doses of radioiodide in Graves' disease: effect on ophthalmopathy and long-acting thyroid stimulator.
    Pequegnat EP; Mayberry WE; McConahey WM; Wyse EP
    Mayo Clin Proc; 1967 Dec; 42(12):802-11. PubMed ID: 4169552
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnosis of Graves' ophthalmopathy without hyperthyroidism: long-acting thyroid stimulator (LATS) determination as laboratory adjunct.
    Gharib H; Mayberry WE
    Mayo Clin Proc; 1970 Jun; 45(6):444-9. PubMed ID: 4193249
    [No Abstract]   [Full Text] [Related]  

  • 17. Neonatal thyrotoxicosis with long acting thyroid stimulator-protector.
    O'Hearlihy C
    Ir Med J; 1977 Mar; 70(4):124-5. PubMed ID: 576864
    [No Abstract]   [Full Text] [Related]  

  • 18. Graves' disease with delayed hyperthyroidism. Onset after several years of euthyroid ophthalmopathy, dermopathy, and high serum LATS.
    Chopra IJ; Solomon DH
    Ann Intern Med; 1970 Dec; 73(6):985-90. PubMed ID: 5538174
    [No Abstract]   [Full Text] [Related]  

  • 19. [Etiopathogenesis of thyrotoxicosis].
    de Medeiros Neto GA
    Rev Paul Med; 1967 Jan; 70(1):48-52. PubMed ID: 5631892
    [No Abstract]   [Full Text] [Related]  

  • 20. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
    Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
    J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.